

CHOEP Therapy– 21 days

INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	*Reimbursement Status
Treatment of T-cell Non-Hodgkins Lymphoma	C85	00396a	Hospital

**If the reimbursement status is not defined¹, the indication has yet to be assessed through the formal HSE reimbursement process.*

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances.

Treatment is administered every 21 days for a maximum of 6 cycles or until disease progression or unacceptable toxicity develops.

Treatment can then be followed by BEAM (Ref NCCP Protocol 00408) and autologous transplant in suitable patients.

Day	Drug	Dose	Route	Diluent & Rate	Cycle
1	Cyclophosphamide	750mg/m ²	IV infusion ¹	250mL 0.9% NaCl over 30 mins	1-6
1	² DOXOrubicin	50mg/m ²	IV Bolus over 15 mins	Into the side arm of a fast running 0.9% NaCl infusion	1-6
1	³ VinCRISTine	1.4mg/m ² (Max 2mg)	IV infusion	50ml minibag 0.9% NaCl over 15minutes	1-6
1-5	Prednisolone ⁴	100mg	PO		1-6
1-3	Etoposide	100mg/m ²	IV infusion	1000mls 0.9% NaCl or over 60minutes	1-6

¹ Cyclophosphamide may also be administered as an IV bolus over 5-10mins

² Lifetime cumulative dose of doxorubicin is 450mg/m²

In establishing the maximal cumulative dose of an anthracycline, consideration should be given to the risk factors belowⁱⁱ and to the age of the patient

³ VincCRISTine is a neurotoxic chemotherapeutic agent.

Refer to NCCP Guidance on the Safe Use of Neurotoxic drugs (including Vinca Alkaloids) in the treatment of cancer [here](#)

⁴ Alternative steroid regimens may be used at consultant discretion

ELIGIBILITY:

- Indications as above
- Age < 60 years
- Adequate haematological, renal and liver status

NCCP Regimen: CHOEP Therapy -21 days	Published: 08/03/2017 Review: 27/03/2021	Version number: 2
Tumour Group: Lymphoma and Myeloma NCCP Regimen Code: 0396	IHS Contributor: Prof Elizabeth Vandenberghe ISMO Contributor: Prof Maccon Keane	Page 1 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

EXCLUSIONS:

- Hypersensitivity to DOXOrubicin, cyclophosphamide, etoposide, vinCRiStine sulphate or any of the excipients.
- A cumulative life-long dose of 450mg/m² of DOXOrubicin should only be exceeded with extreme caution as there is as risk of irreversible congestive heart failure
- Severe liver impairment (etoposide)
- Pregnancy.
- Lactation

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist or by a Consultant Haematologist working in the area of haematological malignancies

TESTS:

Baseline tests:

- FBC, renal and liver profile, LDH, blood glucose.
- ECG
- MUGA or ECHO should be considered prior to the administration of DOXOrubicin in high-risk patients.
- Virology screen -Hepatitis B (HBsAg, HBcoreAb) & C, HIV

*See Adverse Effects/Regimen Specific Complications re Hepatitis B Reactivation

Regular tests:

- FBC, renal and liver profile, LDH prior to each cycle.
- Evaluate for peripheral neuropathy prior to each cycle.
- Cardiac function if clinically indicated

Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant.
- Consider vinCRiStine dose reduction in elderly patients

Haematological:

Table 1: Recommended dose modification in haematological toxicity

ANC x 10 ⁹ /L		Platelets x 10 ⁹ /L	Dose modification
< 1	and/or	< 75	Dose modification not generally indicated. Consider treatment delay and/or add G-CSF.

NCCP Regimen: CHOEP Therapy -21 days	Published: 08/03/2017 Review: 27/03/2021	Version number: 2
Tumour Group: Lymphoma and Myeloma NCCP Regimen Code: 0396	IHS Contributor: Prof Elizabeth Vandenberghe ISMO Contributor: Prof Maccon Keane	Page 2 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Renal and Hepatic Impairment:

Table 2: Recommended dose modification in renal and hepatic impairment

Drug	Renal Impairment		Hepatic Impairment			
Cyclophosphamide	CrCl (ml/min)	Dose	Dose reduction may need to be considered in severe hepatic impairment. Clinical decision			
	>20	100%				
	10-20	75%				
	<10	50%				
DOXOrubicin	No dose reduction required. Clinical decision in severe impairment		Total Bilirubin (micromol/L)		Dose	
			20-51		50%	
			51-85		25%	
			>85		Omit	
			If AST 2-3 x ULN give 75% dose If AST > 3 x ULN give 50% dose			
VinCRISTine	No dose modification required		Total Bilirubin (micromol/L)		AST/ALT Units	Dose
			26-51	or	60-180	50%
			>51	and	Normal	50%
			>51	and	>180	omit
Etoposide	Cr Cl (ml/min)	Dose	Total Bilirubin (micromol/L)		AST	Dose
	>50	100%	26-51	or	60-180	50%
	15-50	75%	>51	or	>180	Clinical decision
	<15	50%				
	Subsequent doses should be based on clinical response					

Management of adverse events:

Table 3: Recommended dose modification of vinCRISTine based on neurotoxicity (CTCAE v4.0)

Symptom	Dose of VinCRISTine
Grade 1	100%
Grade 2	Hold until recovery then reduce dose by 50%
Grade 3,4	Omit

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL: High (Refer to local policy).

PREMEDICATIONS: Not usually required unless the patient has had a previous hypersensitivity.

OTHER SUPPORTIVE CARE:

- G-CSF prophylaxis may be required, please discuss with consultant
- Tumour lysis syndrome prophylaxis – consider use of allopurinol 300mg daily for the first cycle **(Refer to local policy)**
- PJP prophylaxis **(Refer to local policy)**
- Anti-viral prophylaxis **(Refer to local policy)**

NCCP Regimen: CHOEP Therapy -21 days	Published: 08/03/2017 Review: 27/03/2021	Version number: 2
Tumour Group: Lymphoma and Myeloma NCCP Regimen Code: 0396	IHS Contributor: Prof Elizabeth Vandenberghe ISMO Contributor: Prof Maccon Keane	Page 3 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

- Anti-fungal prophylaxis (Avoid the concurrent use of azoles and vinCRISTine (6) **(Refer to local policy)**)
- Prophylactic regimen against vinCRISTine induced constipation is recommended **(Refer to local policy)**.
- Proton Pump Inhibitor while on prednisolone **(Refer to local policy)**
- Patients should have an increased fluid intake of 2-3 litres on day 1 to prevent haemorrhagic cystitis associated with cyclophosphamide.

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Hepatitis B Reactivation:** All patients should be tested for both HBsAg and HBcoreAb. If either test is positive, such patients should be treated with Lamivudine 100 mg/day orally, for the entire duration of chemotherapy and for six months afterwards **(Refer to local policy)**. Such patients should also be monitored with frequent liver function tests and hepatitis B virus DNA at least every two months. If the hepatitis B virus DNA level rises during this monitoring, management should be reviewed with an appropriate specialist with experience managing hepatitis and consideration given to stopping chemotherapy.

VinCRISTine

- **Neuropathy:** vinCRISTine may cause peripheral neuropathy which is dose related and cumulative, requiring monitoring before each dose is administered. The presence of pre-existing neuropathies or previous treatment with other neurotoxic drugs may increase risk of peripheral neuropathy. Patients with mild peripheral neuropathy can usually continue to receive full doses of vinCRISTine, but when symptoms increase in severity and interfere with neurologic function, dose reduction or discontinuation of the drug may be necessary. The natural history following discontinuation of treatment is gradual improvement, which may take up to several months. A routine prophylactic regimen against constipation is recommended for all patients receiving vinCRISTine sulphate. Paralytic ileus may occur. The ileus will reverse itself upon temporary discontinuance of vinCRISTine and with symptomatic care.

DOXOrubicin

- **Cardiac Toxicity:** DOXOrubicin is cardiotoxic and must be used with caution, if at all, in patients with cardiac dysfunction. .
- **Extravasation:** DOXOrubicin and vinCRISTine cause pain and possible tissue necrosis if extravasated **(refer to local policy)**.

DRUG INTERACTIONS:

- DOXOrubicin cardiotoxicity is enhanced by previous or concurrent use of other anthracyclines, or other potentially cardiotoxic drugs (e.g. 5-FU, cyclophosphamide or paclitaxel) or with products affecting cardiac function (e.g. calcium antagonists).
- Current drug interaction databases should be consulted for more information including potential for interactions with CYP3AR inhibitors/ inducers.

ATC CODE:

Cyclophosphamide	-	L01AA01
DOXOrubicin	-	L01DB01
Etoposide	-	L01CB01
VinCRISTine	-	L01CA02

NCCP Regimen: CHOEP Therapy -21 days	Published: 08/03/2017 Review: 27/03/2021	Version number: 2
Tumour Group: Lymphoma and Myeloma NCCP Regimen Code: 0396	IHS Contributor: Prof Elizabeth Vandenberghe ISMO Contributor: Prof Maccon Keane	Page 4 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

REFERENCES:

1. Pfreundschuh M, Trümper L, Kloess M, Schmits R, et al. German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. *Blood* 2004;104:634-41.
2. Pfreundschuh, M, Zwick C, Zeynalova S. et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). *Ann Oncol* 2008;19(3):545-552.
3. Schmitz N, Trümper L, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. *Blood*. 2010;116(18):3418.
4. Dosage Adjustment for Cytotoxics in Renal Impairment January 2009; North London Cancer Network .Available at <http://londoncancer.org/media/65600/renal-impairment-dosage-adjustment-for-cytotoxics.pdf>
5. Dosage Adjustment for Cytotoxics in Hepatic Impairment January 2009; North London Cancer Network. Available at <http://londoncancer.org/media/65594/hepatic-impairment-dosage-adjustment-for-cytotoxics.pdf>
6. Vinca alkaloids + Azoles. Stockley's Drug Interactions 11th Edition
7. Endoxana® Summary of Product Characteristics Accessed Feb 2019. Available at: https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA2299-027-002_21122018112109.pdf
8. DOXorubicin Summary of Product Characteristics Accessed Feb 2019. Available at https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA1658-001-001_16112018114150.pdf
9. Etoposide Summary of Product Characteristics Accessed Feb 2019. Available at https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA1380-168-001_21012019151001.pdf
10. VinCRiStine Summary of Product Characteristics Accessed Feb 2019. Available at https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA0822-232-001_30102018164938.pdf

Version	Date	Amendment	Approved By
1	08/03/2017		Prof Elizabeth Vandenberghe Prof Maccon Keane
2	27/03/2019	Updated to new NCCP template Standardized treatment table Updated dosing modifications in hepatic impairment	Prof Elizabeth Vandenberghe Prof Maccon Keane

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

NCCP Regimen: CHOEP Therapy -21 days	Published: 08/03/2017 Review: 27/03/2021	Version number: 2
Tumour Group: Lymphoma and Myeloma NCCP Regimen Code: 0396	IHS Contributor: Prof Elizabeth Vandenberghe ISMO Contributor: Prof Maccon Keane	Page 5 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

ⁱ ODMS – Oncology Drug Management System

CDS – Community Drug Schemes (CDS) including the High Tech arrangements of the PCRS community drug schemes

Further details on the Cancer Drug Management Programme is available at;

<http://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/>

ⁱⁱ Cardiotoxicity is a risk associated with anthracycline therapy that may be manifested by early (acute) or late (delayed) effects.

Risk factors for developing anthracycline-induced cardiotoxicity include:

- high cumulative dose, previous therapy with other anthracyclines or anthracenediones
- prior or concomitant radiotherapy to the mediastinal/pericardial area
- pre-existing heart disease
- concomitant use of other potentially cardiotoxic drugs

In establishing the maximal cumulative dose of an anthracycline, consideration should be given to the risk factors above and to the age of the patient.

NCCP Regimen: CHOEP Therapy -21 days	Published: 08/03/2017 Review: 27/03/2021	Version number: 2
Tumour Group: Lymphoma and Myeloma NCCP Regimen Code: 0396	IHS Contributor: Prof Elizabeth Vandenberghe ISMO Contributor: Prof Maccon Keane	Page 6 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		